1-11 of 11
Heidi H. Gillenwater
Close
Sort by
Journal Articles

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Clinical Trials & Observations
Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda
Journal: Blood
Blood (2022) 139 (12): 1794–1806.
https://doi.org/10.1182/blood.2021011895
Published: 2022
Includes: Supplemental data
Journal Articles

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda, MD PhD, Kathleen A. Dorritie, MD, Javier Munoz, MD, Deborah M. Stephens, DO, Scott R. Solomon, MD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, Jerill Thorpe, BS, Tanya Siddiqi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-140622
Published: 2020
Journal Articles

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-140491
Published: 2020
Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 593.
https://doi.org/10.1182/blood-2019-127150
Published: 2019
Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 503.
https://doi.org/10.1182/blood-2019-127603
Published: 2019
Journal Articles

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, William G. Wierda, MD PhD, Jason A. Dubovsky, PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Alan Mitchell, MSc, Jerill Thorpe, BSc, Lin Yang, PhD, Kathleen A. Dorritie, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 300.
https://doi.org/10.1182/blood-2018-99-110462
Published: 2018
Journal Articles

Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)

Stuart D Russell, Alexander Lyon, Daniel J. Lenihan, MD, Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MDPhD, Laura Rosiñol, MDPhD, Aleksandr Suvorov, Gianluca Gaidano, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Meletios A. Dimopoulos
Journal: Blood
Blood (2015) 126 (23): 4250.
https://doi.org/10.1182/blood.V126.23.4250.4250
Published: 2015
Journal Articles

Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866)

Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Meletios Dimopoulos
Journal: Blood
Blood (2015) 126 (23): 729.
https://doi.org/10.1182/blood.V126.23.729.729
Published: 2015
Journal Articles

Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup

Antonio Palumbo, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Douglas Joshua
Journal: Blood
Blood (2015) 126 (23): 1844.
https://doi.org/10.1182/blood.V126.23.1844.1844
Published: 2015
Journal Articles

Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)

Wee-Joo Chng, Hartmut Goldschmidt, Meletios A. Dimopoulos, Philippe Moreau, Douglas Joshua, Antonio Palumbo, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Roman Hájek
Journal: Blood
Blood (2015) 126 (23): 30.
https://doi.org/10.1182/blood.V126.23.30.30
Published: 2015
Journal Articles

A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies

Michael R. Savona, MD, FACP, Jesus G. Berdeja, MD, Susan J Lee, Hansen Wong, PhD, Ju RueyJiuan Lee, PhD, Heidi H. Gillenwater, MD, David S. Siegel, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 203.
https://doi.org/10.1182/blood.V120.21.203.203
Published: 2012